Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 486 | 58 | 428 |
| Samples | 141 | 34 | 107 |
| Peptides | 107 | 30 | 81 |
Function
RBFOX3 · RNA binding fox-1 homolog 3
This gene encodes a member of the RNA-binding FOX protein family which is involved in the regulation of alternative splicing of pre-mRNA. The protein has an N-terminal proline-rich region, an RNA recognition motif (RRM) domain, and a C-terminal alanine-rich region. This gene produces the neuronal nuclei (NeuN) antigen that has been widely used as a marker for post-mitotic neurons. This gene has its highest expression in the central nervous system and plays a prominent role in neural tissue development and regulation of adult brain function. Mutations in this gene have been associated with numerous neurological disorders. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, May 2017].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000583458 | J3QRF4* | 121 | 75 |
| ENST00000580155 | A6NFN3 | 115 | 70 |
| ENST00000584778 | A6NFN3-2 | 115 | 70 |
| ENST00000582043 | J3QQZ2* | 110 | 64 |
| ENST00000693108 | A0A8I5KWJ3* | 25 | 23 |
Gene Properties
Recurrent Mutations
All 70 amino-acid changes on canonical ENST00000580155 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RBFOX3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RBFOX3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Acute Monocytic Leukemia | 0/1 0% | 2/25 8% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 20/1592 1% |
| Endometrial Carcinoma | 3/42 7% | 5/612 1% |
| Melanoma | 4/210 2% | 14/1899 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 4/1390 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Solid Cancers | 0/94 0% | 8/1515 1% |
| Neuroendocrine Tumour | 3/154 2% | 0/577 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| Colorectal Carcinoma | 5/143 4% | 7/3239 0% |
| Bladder Carcinoma | 1/58 2% | 2/956 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Neuroblastoma | 0/87 0% | 3/1331 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 3/2534 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Gastric Carcinoma | 0/74 0% | 3/1809 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 2/2640 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 0/810 0% |
| Breast Carcinoma | 1/144 1% | 3/3264 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
Mutation Distribution
Where RBFOX3 is mutated · all tissues, split by cell line vs tissue
How many mutations in RBFOX3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 486 mutations in RBFOX3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|